Paramagnetic polymerized liposomes as new recirculating MR contrast agents

被引：54

作者：

Storrs, RW ^{[1
]}

Tropper, FD ^{[1
]}

Li, HY ^{[1
]}

Song, CK ^{[1
]}

Sipkins, DA ^{[1
]}

Kuniyoshi, JK ^{[1
]}

Bednarski, MD ^{[1
]}

Strauss, HW ^{[1
]}

Li, KCP ^{[1
]}

机构：

[1] STANFORD UNIV,MED CTR,DEPT RADIOL,LUCAS MRS IMAGING CTR,STANFORD,CA 94305

来源：

JMRI-JOURNAL OF MAGNETIC RESONANCE IMAGING | 1995年 / 5卷 / 06期

关键词：

contrast agents; liposomes; blood pool; biodistribution;

D O I：

10.1002/jmri.1880050617

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We describe a well-tolerated blood pool contrast agent with extended recirculatory half-life based on paramagnetic polymerized liposomes (PPLs), PPLs were constructed from a new type of polymerizable lipid molecule that has a derivative of gadopentetate dimeglumine as the hydrophilic head group and diacetylene groups in the hydrophobic acyl chains, which cross-link when irradiated with ultraviolet (UV) light. Biodistribution, blood pool half-life, and MR image enhancement were determined for PPLs composed of 10% of the gadopentetate dimeglumine lipid and 90% of ditricosadiynoyl tricosadiynayl phosphatidylcholine (DAPC) at a dose of 0.015 mmol Gd+3/kg in rats, In T1-weighed MR images (TR/TE = 400/18 msec), an average signal enhancement of 34% in the kidneys and 20% in the liver was observed, which persisted for at least 90 minutes after administration of the PPLs, Biodistribution studies using radiolabeled PPLs confirmed that 80% of the injected dose remained in the blood pool after 2 hours, The half-life of elimination from the blood pool was 19 hours. The preparation was well tolerated in rats and produced similar MR contrast enhancement of the blood pool as produced by other liposome contrast agents, However, the half-life of PPL elimination from the blood pool was prolonged relative to other liposome systems.

引用

页码：719 / 724

页数：6

共 62 条

[1]

Gregortadis G, Allison AC, Liposomes as drug carriers: recent trends and progress, pp. 1-865, (1988)

[2]

Fldler IJ, Berestein G, Liposomes in the therapy of infectious diseases and cancer, pp. 1-480, (1989)

[3]

Regen SL, Liposomes: from biophysics to therapeutics, pp. 1-73, (1987)

[4]

Phillips ML, Nudelman E, Gaeta FC, Et al., ELAM‐1 mediates cell adhesion by recognition of a carbohydrate ligand. sialyl‐Lex, Science, 250, pp. 1130-1132, (1990)

[5]

Spevak WS, Nagy JO, Charych DH, Schaefer ME, Gilbert JH, Bednarski MD, Polymerized liposomes containing c‐glycosides of sialic acid are potent inhibitors of influenza virus in vitro infectivity, J Am Chem Soc, 116, pp. 1146-1147, (1994)

[6]

Kingery-Wood JE, Williams KW, Sigal GB, Whitesides GM, The agglutination of erythrocytes by influenza virus is strongly inhibited by liposomes incorporating an analog of sialyl ganglio‐sides, Journal of the American Chemical Society, 114, pp. 7303-7305, (1992)

[7]

Bezouska K, Yuen C-T, O'Brien J, Et al., Oligosaccharide 11‐gands for NKR‐P1 protein activate NK cells and cytotoxicity, Nature, 372, pp. 150-157, (1994)

[8]

Zhu N, Liggit YL, Debs R, Systemic gene expression after intravenous DNA delivery into adult mice, Science, 261, pp. 209-211, (1993)

[9]

Duzgunes N, Feigner PL, Intracellular delivery of nucleic acids and transcriptions factors by cationic liposomes, Methods En‐zymol, 221, pp. 303-306, (1993)

[10]

Feigner JH, Kumar R, Sridhar CN, Et al., Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations, J Biol Chem, 269, pp. 2550-2561, (1994)

← 1 2 3 4 5 6 7 →